Related Experiment Videos
Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas
1Molecular Neurogenetics Unit, Massachusetts General Hospital, Boston 02129.
Abstract:
The CDKN2 gene that encodes the cell cycle regulatory protein cyclin-dependent kinase-4 inhibitor (p16) has recently been mapped to chromosome 9p21. Frequent homozygous deletions of this gene have been documented in cell lines derived from different types of tumors, including breast tumors, suggesting that CDKN2 is a tumor suppressor gene involved in a wide variety of human cancers. To determine the frequency of CDKN2 mutations in breast carcinomas, we screened 37 primary tumors and 5 established breast tumor cell lines by single-strand conformation polymorphism analysis. In addition, Southern blot analysis was performed on a set of five primary breast carcinoma samples and five breast tumor cell lines. Two of the five tumor cell lines revealed a homozygous deletion of the CDKN2 gene, but no mutations were observed in any of the primary breast carcinomas. These results suggest that the mutation of the CDKN2 gene may not be a critical genetic change in the formation of primary breast carcinoma.
Insights
The CDKN2 gene, encoding cyclin-dependent kinase-4 inhibitor (p16), is frequently deleted in tumor cell lines. However, this study found no CDKN2 mutations in primary breast carcinomas, suggesting it
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The CDKN2 gene, encoding cyclin-dependent kinase-4 inhibitor (p16), is located on chromosome 9p21.
- Homozygous deletions of CDKN2 are frequent in various tumor cell lines, suggesting its role as a tumor suppressor.
- CDKN2 is implicated in a broad spectrum of human cancers.
Purpose of the Study:
- To investigate the frequency of CDKN2 gene mutations in primary breast carcinomas.
- To assess the role of CDKN2 gene alterations in breast cancer development.
Main Methods:
- Screening of 37 primary breast tumors and 5 breast tumor cell lines using single-strand conformation polymorphism (SSCP) analysis.
- Southern blot analysis was performed on five primary breast carcinoma samples and five breast tumor cell lines.
Main Results:
- Two out of five tested breast tumor cell lines exhibited homozygous deletion of the CDKN2 gene.
- No CDKN2 gene mutations were detected in any of the 37 primary breast carcinomas analyzed.
Conclusions:
- The findings suggest that CDKN2 gene mutation is not a critical genetic event in the pathogenesis of primary breast carcinoma.
- While deletions occur in cell lines, mutations are infrequent in primary tumors, indicating a potentially limited role in early breast cancer formation.